Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Available for licensing from NIH: BOG gene and protein product for Rx, Dx use

Feb. 15, 1999

U. of Arizona prepares novel cyanoaziridine-based antitumor agents

Feb. 15, 1999

ProScript initiates second phase I trial for PS-341

Feb. 15, 1999

Aronex initiates phase I/II trial of Atragen + interferon alfa in renal cell carcinoma

Feb. 15, 1999

Positive preclinical results for NuChem's anticancer compounds in lung cancer model

Feb. 12, 1999

TNP-470 inhibits human lung tumor growth and neovascularization

Feb. 11, 1999

Roberts enriches product pipeline with addition of RL-0903

Feb. 11, 1999

Bristol-Myers Squibb and EntreMed modify research agreement

Feb. 11, 1999

Platinum-based chemotherapy for ovarian cancer increases risk of leukemia

Feb. 11, 1999

Combination of TZT-1027 + ara-C provides synergistic antitumor activity

Feb. 10, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.